Abstract: Disclosed in the present invention are an antigen binding protein targeting CD40, and the preparation therefor and the use thereof. The antigen binding protein targeting CD40 has the characteristics of a high affinity to CD40 and a strong agonistic activity on signaling pathways, particularly the enhanced agonistic activity after crosslinking, so that the antigen binding protein targeting CD40 has a larger therapeutic window, and is expected to bring about new opportunities for the treatment of various tumors.

Abstract: Disclosed are an antigen-binding protein targeting PD-L1 and CD40, preparation therefor, and use thereof. The antigen-binding protein targeting PD-L1 and CD40, by means of blocking a PD-1/PD-L1 inhibitory signaling pathway, acting on an activated CD40 receptor, and simultaneously activating an antigen-presenting cell and a lymphocyte, achieves a significant synergistic anti-tumor effect; meanwhile, the activation of the antigen-binding protein targeting PD-L1 and CD40 on an immune cell only occurs at a tumor microenvironment site, so that problems of systemic drug toxicity and side effects are significantly solved, which enables the antigen-binding protein targeting PD-L1 and CD40 to exert an excellent anti-tumor efficacy under very safe conditions.

Abstract: Disclosed in the present invention is an antibody targeting CD25 or a variant thereof. A monoclonal antibody targeting CD25 is a naturally occurring antibody, has an activity of binding to human CD25 and cynomolgus monkey CD25, and has a stronger ADCC effect after being modified with Fc. In-vitro experiments show that the antibody has the effect of clearing Treg and lymphoma cells without blocking an IL-2 signaling pathway.

Abstract: A method for performing a polymer flood of a hydrocarbon-bearing, subterranean reservoir (5) includes (a) injecting a polymer solution from an injection well (32) into the subterranean reservoir to form a polymer slug (44) in the subterranean reservoir, wherein the polymer slug has a leading front (46) and a trailing rear (48), and an S-shaped graded viscosity profile which decreases convexly in viscosity from the front of the polymer slug to an inflection point and concavely in viscosity from the inflection point to the rear of the polymer slug, (b) injecting an aqueous solution (50) from the injection well into the subterranean reservoir following (a) to displace the polymer slug through the subterranean reservoir.

Abstract: The present invention relates to a specific binding protein targeting PD-L1 and CD73, wherein the specific binding protein is capable of specifically binding to PD-L1 and/or a fragment thereof, and CD73 and/or a fragment thereof. The present invention further relates to use of the specific binding protein in the treatment, prevention and/or diagnosis of diseases such as immune diseases, acute and chronic inflammatory diseases, and tumor diseases.

Abstract: Provided are an antigen binding protein capable of binding to PD-1 and a fusion protein thereof, and corresponding preparation method therefor and the use thereof. The fusion protein is capable of targeting PD-1 and CD73.

Abstract: Disclosed is a binding protein having at least two protein functional regions, the binding protein comprising a protein functional region A and a protein functional region B; the protein functional region A and the protein functional region B target different antigens or epitopes, the protein functional region A is a Fab or a scFv structure, the protein functional region B is a VH structure, and there are one or more of each of the protein functional region A and the protein functional region B. A multi-specific binding protein has a smaller molecular weight, fewer polypeptide chains, and a simpler structure. By means of different structure types, relative positions, binding valence and other parameters, the functional activities for different targets can be adjusted, and then different combinations of activities can be designed so as to meet the needs of different dose combinations of clinical combinations.

Abstract: Anti-PD-1 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancers and autoimmune diseases.

Abstract: Provided herein are anti-PD-L1 antibodies and antigen-binding fragments thereof. Also provided are nucleic acids encoding the antibodies, compositions containing the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, infectious diseases and autoimmune diseases.

Abstract: Provided herein are anti-PD-L1 antibodies and antigen-binding fragments thereof. Also provided are nucleic acids encoding the antibodies, compositions containing the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, infectious diseases and autoimmune diseases.

Abstract: Anti-PD-1 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancers and autoimmune diseases.